BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales

Key Takeaways Bausch Health's Q3 EPS of $1.16 and revenues of $2.68B beat consensus estimates.Salix revenues jumped 12%, led by 16% growth in Xifaxan sales on solid demand.Company raised 2025 revenue outlook, now guiding up to $10.050-$10.250B for the year.Bausch Health Companies Inc. (BHC) reported better-than-expected results for the third quarter of 2025. Shares gained 7.3% in after-market hours trading in response to the quarterly performance.Adjusted earnings per share of $1.16 comfortably beat the Zac ...